MedinCell S.A. (EPA:MEDCL)
34.58
+0.68 (2.01%)
Oct 20, 2025, 1:44 PM CET
MedinCell Revenue
In the fiscal year ending March 31, 2025, MedinCell had annual revenue of 27.73 million EUR with 132.12% growth. MedinCell had revenue of 18.29 million in the half year ending March 31, 2025, with 207.64% growth.
Revenue
27.73M
Revenue Growth
+132.12%
P/S Ratio
40.46
Revenue / Employee
211.66K
Employees
131
Market Cap
1.12B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 27.73M | 15.78M | 132.12% |
Mar 31, 2024 | 11.95M | -1.71M | -12.52% |
Mar 31, 2023 | 13.66M | 5.32M | 63.77% |
Mar 31, 2022 | 8.34M | 152.00K | 1.86% |
Mar 31, 2021 | 8.19M | 2.19M | 36.43% |
Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sanofi | 45.74B |
EssilorLuxottica Société anonyme | 27.24B |
Eurofins Scientific SE | 7.14B |
emeis Société anonyme | 5.77B |
Clariane SE | 5.31B |
bioMérieux | 4.12B |
Ipsen | 3.76B |
Sartorius Stedim Biotech | 2.95B |
MedinCell News
- 9 days ago - Teva : FDA Grants Expanded Approval For UZEDY To Treat Bipolar I Disorder In Adults - Nasdaq
- 4 weeks ago - Medincell Reports Positive Phase 3 Safety Data For Olanzapine LAI; No PDSS Observed - Nasdaq
- 9 months ago - Teva Pharmaceuticals reports completion of phase 3 trial for Olanzapine LAI in Schizophrenia - Seeking Alpha